Resistance to PDAC treatment has been associated with SMAD4 loss limiting the vulnerability of pancreatic cancer cells to complex I inhibition via the promotion of mitophagy (Ezrova et al., 2021). The gene discussed is SMAD4; the disease is pancreatic neoplasm.